Simonet and colleagues characterized osteoprotegerin, a newly identified secreted protein of the TNF receptor family, and tested how it affects osteoclasts and bone mass.
Laboratory discovery study in transgenic mice, normal mice, ovariectomized rats and osteoclast precursor cultures.
Key Findings
Mice with transgenic liver expression of OPG developed marked osteopetrosis that was not fatal.
The osteopetrosis in these mice coincided with fewer cells reaching the late stages of osteoclast differentiation.
Recombinant OPG given to normal mice reproduced the effects seen in the transgenic animals.
In culture, recombinant OPG blocked osteoclast formation from precursors, with greater inhibition at higher doses.
OPG prevented the bone loss that followed ovariectomy in rats.
Board pearl
OPG is a secreted protein of the TNF receptor superfamily that blocks osteoclast differentiation, so an excess of it produced osteopetrosis in mice.
Authors' conclusion
These data show that OPG can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.
Simonet and colleagues characterized osteoprotegerin, a newly identified secreted protein of the TNF receptor family, and tested how it affects osteoclasts and bone mass.
Laboratory discovery study in transgenic mice, normal mice, ovariectomized rats and osteoclast precursor cultures.
Key Findings
Mice with transgenic liver expression of OPG developed marked osteopetrosis that was not fatal.
The osteopetrosis in these mice coincided with fewer cells reaching the late stages of osteoclast differentiation.
Recombinant OPG given to normal mice reproduced the effects seen in the transgenic animals.
In culture, recombinant OPG blocked osteoclast formation from precursors, with greater inhibition at higher doses.
OPG prevented the bone loss that followed ovariectomy in rats.
Board pearl
OPG is a secreted protein of the TNF receptor superfamily that blocks osteoclast differentiation, so an excess of it produced osteopetrosis in mice.
Authors' conclusion
These data show that OPG can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.